AI Article Synopsis
Article Abstract
Introduction: The Global Alzheimer's Association Interactive Network (GAAIN) is consolidating the efforts of independent Alzheimer's disease data repositories around the world with the goals of revealing more insights into the causes of Alzheimer's disease, improving treatments, and designing preventative measures that delay the onset of physical symptoms.
Methods: We developed a system for federating these repositories that is reliant on the tenets that (1) its participants require incentives to join, (2) joining the network is not disruptive to existing repository systems, and (3) the data ownership rights of its members are protected.
Results: We are currently in various phases of recruitment with over 55 data repositories in North America, Europe, Asia, and Australia and can presently query >250,000 subjects using GAAIN's search interfaces.
Discussion: GAAIN's data sharing philosophy, which guided our architectural choices, is conducive to motivating membership in a voluntary data sharing network.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817494 | PMC |
| http://dx.doi.org/10.1016/j.jalz.2015.06.1896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The neuroprotective role of volatile oils: insights into chemical profiles, characteristics, neurochemical mechanisms, and preclinical studies in Alzheimer's disease.
Inflammopharmacology
January 2025
Department of Community Medicine, Vidhyadeep Homoeopathic Medical College and Research Centre, Vidhyadeep University, Anita, Surat, Gujarat, 394110, India.
Volatile oils (VOs), synonymously termed essential oils (EOs), are highly hydrophobic liquids obtained from aromatic plants, containing diverse organic compounds for example terpenes and terpenoids. These oils exhibit significant neuroprotective properties, containing antioxidant, anti-inflammatory, anti-apoptotic, glutamate activation, cholinesterase inhibitory action, and anti-protein aggregatory action, making them potential therapeutic agents in managing neurodegenerative diseases (NDs). VOs regulate glutamate activation, enhance synaptic plasticity, and inhibit oxidative stress through the stimulation of antioxidant enzymes.
View Article and Find Full Text PDF[Overview of the French Memory Centres healthcare pathway for patients with early Alzheimer disease].
Geriatr Psychol Neuropsychiatr Vieil
September 2024
CMRR CHU Toulouse, IHU Health Age, Toulouse, UMR 1297 CERPOP.
The growing prevalence of the Alzheimer's disease (AD) is an increasing public health concern that led to French recommendations for timely AD diagnosis and patient management as well as a territorial coverage of specialized structures [Memory Centers including Resources and Memory Research Centers (RMRC) and Memory Consultations (MC)]. In view of the potential availability of Disease Modifying Therapies (DMTs), this French observatory aimed to describe the current organization of the Memory Centers, and the care pathway of patients suffering from early AD. Overall, 12 of the 28 RMRC and 44 of the 250 MC solicited by the Federation of Memory Centers participated in this study.
View Article and Find Full Text PDFProtocol for the systematic review of age and sex in preclinical models of age-correlated diseases.
F1000Res
January 2025
German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), Berlin, Berlin, Germany.
The translation of animal-based biomedical research into clinical research is often inadequate. Maximizing translation should be central to animal research on human diseases, guiding researchers in study design and animal model selection. However, practical considerations often drive the choice of animal model, which may not always reflect key patient characteristics, such as sex and age, impacting the disease's course.
View Article and Find Full Text PDFPerspective: Minimally clinically important "symptomatic" benefit associated with disease modification resulting from anti-amyloid immunotherapy.
Alzheimers Dement (N Y)
January 2025
Unlabelled: Despite some skepticism regarding the amyloid hypothesis, there is growing evidence that clearing amyloid by targeting specific species of amyloid (plaque, oligomers, fibrils, and protofibrils) for removal has therapeutic benefits. Specifically, there is growing evidence that, in mild cognitive impairment and mild dementia due to Alzheimer's disease (AD), robust and aggressive removal of amyloid can slow cognitive decline as measured by global instruments, composite measures, and cognitive testing. Furthermore, clinical efficacy signals coupled with clear biomarker changes provide the first evidence of disease modification.
View Article and Find Full Text PDF[The Advancement of Elderly Care: Development and Application of an Interdisciplinary Outpatient Dementia Care Consultation Module].
Hu Li Za Zhi
February 2025
Department of Nursing, College of Medicine, National Cheng Kung University, Taiwan, ROC.
With population aging, dementia has become a significant global health issue. Most people with dementia live in the community, are cared for by family members, and face complex and multifaceted care challenges. In line with Taiwan's Long-Term Care 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!